Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome.

What Was Tested

The paper reports a study of Follicle Stimulating Hormone, published as a randomized controlled trial.

To investigate possible differences between using recombinant FSH (rFSH) and hMG for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.

Who Took Part

The study group was 578 patients.

The age groups tagged for this paper are adults, women only.

A total of 578 patients of their IVF/ICSI routine were recruited.

Treatment with hMG was used for 282 patients (282 cycles), whereas 296 patients (296 cycles) were treated with rFSH.

How the Study Was Run

The researchers set it up as a randomized and parallel-group study.

Because people in this Follicle Stimulating Hormone study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the patients stayed in one arm throughout.

A tertiary care infertility clinic.

The number of cycles leading to an embryo transfer were 248 and 259, respectively.

What Was Measured

The subject headings attached to it are Embryo Transfer, Fertilization in Vitro, Follicle Stimulating Hormone, Infertility, Menotropins, Recombinant Proteins and Sperm Injections, Intracytoplasmic.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Follicle Stimulating Hormone in 578 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2001 (Fertility and sterility), a journal based in United States.

More context: all human trials.